Timing clarification: Intuitive Surgical’s Q2 earnings call is scheduled for today, Thursday, July 16, 2026, at 1:30 p.m. Pacific, not tomorrow. The report is expected after the market close. (isrg.gcs-web.com)
The central question is not whether Intuitive Surgical will produce another quarter of double-digit growth. It is whether procedure growth remains strong enough to sustain the premium valuation and offset recent concerns about weakening hospital surgical volumes.
ISRG enters the report with unusually divided signals:
My view: Procedure growth, gross-margin guidance and management’s comments about U.S. hospital demand will matter more than a modest EPS beat. Given the reset in the share price, expectations are less demanding than they were at the start of the year—but this remains a stock where the quality of the outlook matters more than the headline quarter.
Consensus varies modestly by data provider:
| Metric | Q2 2026 consensus | Q2 2025 actual | Implied growth |
|---|---|---|---|
| Revenue | $2.81B–$2.82B | $2.44B | 15%–16% |
| Adjusted EPS | $2.41–$2.48 | $2.19 | 10%–13% |
Zacks places consensus at $2.81 billion and $2.48, while Benzinga lists $2.82 billion and $2.41. (tradingview.com)
The comparison is not especially difficult financially: Q2 2025 revenue grew 21%, adjusted EPS was $2.19, da Vinci procedures grew 17%, and the company placed 395 da Vinci systems, including 180 da Vinci 5 systems. (isrg.gcs-web.com)
However, Q1 2026 set a high near-term bar. ISRG reported $2.77 billion of revenue, $2.50 of adjusted EPS, a 67.8% adjusted gross margin and 431 da Vinci placements, including 232 da Vinci 5 systems. (isrg.gcs-web.com)
ISRG’s economic engine remains procedure volume. Procedures create instruments-and-accessories revenue, stimulate service revenue and eventually drive demand for additional systems.
Management’s current full-year da Vinci procedure-growth outlook is 13.5%–15.5%, raised from 13%–15% after Q1. Q1 da Vinci growth of 16% put ISRG ahead of that annual range. (isrg.gcs-web.com)
The most important Q2 number is therefore likely to be:
Can da Vinci procedure growth remain near 15%–16%, or did U.S. surgical demand weaken materially during the quarter?
The recent HCA warning makes this question more urgent. On the positive side, ISRG’s Q1 U.S. growth was supported by general surgery, acute procedures and a 31% increase in after-hours procedures. Those categories may be more resilient than purely elective surgery. Conversely, a broad hospital-volume slowdown could affect both procedures and capital purchases.
Interpretation:
Investors should also separate da Vinci procedure growth from the combined da Vinci/Ion figure. Ion is growing much faster from a smaller base and can make total procedure growth look somewhat stronger.
The da Vinci 5 rollout is doing more than adding capital revenue. In Q1:
This combination—higher pricing, more utilization, service revenue and trade-in activity—is the main reason ISRG’s revenue has recently grown faster than procedures.
For Q2, the placement total is less important than the composition:
A quarter with strong da Vinci 5 adoption but somewhat softer total placements could still be constructive. Placements are inherently lumpy, while utilization is the better indicator of long-term recurring revenue.
Management also announced more than 100 planned updates and user-experience improvements to da Vinci 5, extended uses for most Force Feedback instruments, and reported actual system uptime above 99%. These enhancements reinforce the platform’s differentiation, but investors will want evidence that they are translating into measurable utilization and customer economics. (isrg.gcs-web.com)
Q1 instruments-and-accessories revenue rose 23% to $1.69 billion, well ahead of 16% da Vinci procedure growth. Management attributed the difference partly to:
Recurring revenue represented 86% of Q1 revenue, which remains an important strength. But the unusually large gap between procedure growth and instruments-and-accessories growth may not repeat.
A healthier Q2 result would show:
A top-line miss caused mainly by the normalization of distributor orders would be less concerning than a miss caused by weak procedures. Investors should read the revenue bridge carefully.
Management currently expects a 2026 adjusted gross margin of 67.5%–68.5%, including approximately 100 basis points of tariff pressure. Q1 came in at 67.8%. (isrg.gcs-web.com)
Q1 benefited from strong fixed-cost leverage and product-cost reductions, but management warned that freight, oil-related inputs and semiconductor memory costs would become more unfavorable during the remainder of 2026.
The margin debate is therefore balanced:
Potential positives
Potential negatives
A Q2 adjusted gross margin around or above 68% would be encouraging. A result below approximately 67.5%, accompanied by cautious second-half commentary, would likely overshadow an EPS beat.
International procedure growth was 19% in Q1, with strength in India, Canada, the U.K., Korea and Taiwan. But China and Japan remain the major swing factors.
The environment remains difficult because of:
Management previously said it did not expect clarity on important Chinese reimbursement matters until 2027. Investors should not expect a sudden Q2 turnaround. The key is whether conditions are stabilizing or deteriorating further.
Japan received several constructive policy changes effective in June 2026:
Because these changes began late in Q2, they are unlikely to have a large immediate financial effect. Management’s comments about early hospital interest and the second-half placement pipeline will be more useful than the reported Q2 numbers.
Europe was a source of placement strength in Q1, particularly the U.K., but management has continued to flag possible capital pressure from government budgets and shifting priorities. Investors should watch whether European capital demand held up after a strong Q1.
Q1 SP procedures grew 68%, while Ion procedures grew 39%. These platforms are not yet as financially important as multi-port da Vinci, but they broaden ISRG’s addressable market and support its long-term growth case.
For SP, watch:
For Ion, watch:
The quarter would be stronger if Ion and SP maintain rapid growth without requiring disproportionate spending or depressing consolidated margins.
Current 2026 guidance is:
| Metric | Current outlook |
|---|---|
| Da Vinci procedure growth | 13.5%–15.5% |
| Adjusted gross margin | 67.5%–68.5% |
| Adjusted operating-expense growth | 11%–14% |
| Stock-based compensation | $890M–$920M |
| Other income | $315M–$335M |
| Adjusted tax rate | 22%–23% |
The procedure outlook is the most likely item to move. After a 16% Q1, another quarter near 16% would make the current midpoint look conservative. But management may hesitate to raise guidance aggressively because of hospital-volume uncertainty, China, Japan, tariffs and tough second-half comparisons.
A simple reaffirmation could be interpreted in two ways:
Gross-margin guidance is the next most important item. A procedure-guidance increase paired with a margin reduction would be a mixed result.
ISRG ended Q1 with nearly $8 billion of cash and investments after repurchasing $1.1 billion of stock. In April, the board increased the total repurchase authorization to $5 billion. (isrg.gcs-web.com)
With the stock substantially below its Q1 repurchase levels, investors should watch:
Buybacks do not change the operating thesis, but meaningful repurchases at lower prices could improve per-share earnings growth and signal management confidence.
The following are my thresholds, not Street consensus:
| Scenario | What it might look like | Likely interpretation |
|---|---|---|
| Bull | Da Vinci procedures ≥16%; revenue above $2.9B; adjusted EPS above $2.55; gross margin ≥68%; procedure guidance raised | Confirms ISRG-specific strength despite weaker hospital data; supports valuation stabilization or expansion |
| Base | Procedures 14.5%–15.5%; revenue $2.80B–$2.88B; EPS $2.42–$2.52; guidance maintained | Solid execution, but stock reaction depends heavily on management’s tone and U.S. procedure commentary |
| Bear | Procedures ≤13.5%; revenue below $2.78B; gross margin below 67.5%; guidance lowered or framed toward low end | Suggests hospital weakness is reaching ISRG and challenges the premium multiple |
ISRG does not need another Q1-sized EPS surprise to deliver a credible quarter. It does need to demonstrate that its core procedure franchise remains resilient.
The best result would combine:
The principal risk is a quarter that meets headline EPS expectations but reveals weakening procedures, normalized recurring-revenue growth and a more cautious second-half outlook.
After the stock’s roughly 31% year-to-date decline, the setup is more balanced. But at approximately 37 times the current 2026 EPS estimate, “good enough” numbers may not be enough unless management also preserves confidence in durable mid-teens procedure growth.